MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Substance Abuse, Substance Use Disorder (SUD)_Opioid, Alcohol, Tobacco, Etc.
Aquestive Therapeutics, Inc. (NASDAQ: AQST), formerly, MonoSolRx*
Organization & Developments: Aquestive
Parents
Aquestive Therapeutics, Inc. (NASDAQ: AQST), formerly, MonoSolRx*
Children
*Anti-nausea drug called ondansetron (Zuplenz)
*Hopes to be the first company to successfully make oral insulin—long the holy grail of the pharmaceutical industry
*It’s working on transforming a number of existing drugs into films, including montelukast (Singulair) for allergy and asthma, and zolmitriptan (Zomig) for migraine.
*MonoSol Rx’s drug-delivery technology, called PharmFilm, is reminiscent of Johnson & Johnson’s popular breath freshener Listerine PocketPaks
*Some big pharma companies are doing their own work with film, including Novartis, which has made over-the-counter film versions of Triaminic, Theraflu, and other famous products
*The company secured more than 20 patents covering everything from the composition of the film to the flavoring that’s used to mask medicines’ often bitter tastes.
*The film product has captured 37.5 percent of total sales of buprenorphine, which is also available as a dissolving tablet
*The two companies developed a film containing evenly distributed insulin-bearing nanoparticles
*Treatment for opioid dependence that MonoSol Rx developed with Richmond, VA-based Reckitt Benckiser Pharmaceuticals, which markets the drug as Suboxone Film.
2011: Drugs that Melt in Your Mouth: MonoSolRx Has Its Sights Set on Oral Insulin (2011)
2017: MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio
2019: Aquestive Therapeutics: Finally Looking For Entry Ahead Of Key Catalysts_seekingalpha.com
2019: Aquestive Therapeutics: Specialty Pharma Company With Multiple Value Drivers_seekingalpha.com
2020: Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters Nasdaq:AQST
2020: Aquestive Therapeutics: Back From The Brink, ~57% Upside Potential In New Asset Structuring
2021: Aquestive Therapeutics: Remaining Bullish On PharmFilm Technology Opportunities
2021: Aquestive Therapeutics: Remaining Bullish On PharmFilm Technology Opportunities
2022: Aquestive Therapeutics Receives FDA Fast Track Designation
2022: Aquestive Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Aquestive Therapeutics: FDA Stymies Libervant Launc_seekingalpha.com
2022: Aquestive Therapeutics: Going All-In On AQST-109_seekingalpha.com
2022: Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics_seekingalpha.com
2022: Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant_seekingalpha.com
2024: Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
2024: Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
2024: Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
2024: Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1_ seekingalpha.com
2024: Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
2024: Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024_ seekingalpha
2024: Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
2024: Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
2024: Aquestive: Rare Opportunity With Dual Platform Strategy_seekingalpha.com
2024: Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
2025: Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate
2025: Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
2025: Aquestive Therapeutics: Five Foci For 2025
2026: Aquestive Therapeutics (AQST): Anaphylm Will Probably Survive This Regulatory Hurdle
Jumps
*Key People: Aquestive
Finance & Acquisitions: Aquestive